Recent developments include patent grants for Anixa's breast cancer vaccine technology in Australia, South Korea, and China, and presentation of positive Phase 1 clinical trial data for the breast cancer vaccine. The company continues clinical trials of its CAR-T therapy for ovarian cancer and maintains buy recommendations from analysts.

• Anixa gained patent protection in Australia for its breast cancer vaccine technology [N3].
• The company won a South Korean patent for its breast cancer vaccine [N4].
• Anixa received a notice of allowance for its breast cancer vaccine technology patent in China [N5].
• Final data from the Phase 1 clinical trial of the breast cancer vaccine showed safety, tolerability, and immune response in 74% of subjects [N7].
• D. Boral Capital maintained a buy recommendation on Anixa Biosciences in December 2025 [N6].
• Clinical testing of the CAR-T therapy lira-cel for ovarian cancer continues with multiple dose cohorts treated and generally well-tolerated [S1].

The company has demonstrated progress in clinical development with its CAR-T therapy and breast cancer vaccine, including positive safety and immune response data. Patent grants in key markets such as Australia, South Korea, and China enhance its intellectual property portfolio. Collaborations with top research institutions and government grants support ongoing innovation. Anixa's strong liquidity provides runway to advance clinical programs and explore additional cancer vaccine targets, potentially enabling future licensing opportunities with larger pharmaceutical companies.

Anixa has not yet generated revenue from its therapeutics or vaccine programs and continues to incur net losses. Clinical development carries inherent risks including uncertain efficacy and regulatory outcomes. The company depends on milestone payments and licensing agreements, which may be delayed or not materialize. Competition in oncology immunotherapy is intense, and the path to commercialization is lengthy and capital intensive. Financial resources, while currently sufficient, may require augmentation to sustain long-term development and operations.

Anixa's moat is based on its exclusive worldwide licenses to novel immunotherapy and vaccine technologies from reputable institutions such as The Wistar Institute and Cleveland Clinic. Its proprietary CAR-T therapy and cancer vaccine platforms target specific proteins associated with difficult-to-treat cancers, supported by clinical trial data and patent protections in multiple jurisdictions. Collaborations with leading cancer research centers and government funding further strengthen its competitive position in the oncology biotech space.

• Clinical Development Risk: The success of Anixa's CAR-T therapy and cancer vaccines depends on clinical trial outcomes, which are uncertain and may not demonstrate efficacy or safety sufficient for regulatory approval.
• Regulatory Risk: Obtaining and maintaining regulatory approvals for novel therapies and vaccines involves complex processes with potential delays or denials.
• Financial Risk: The company has reported net losses and relies on external funding and licensing agreements; insufficient capital could impede development progress.
• Market and Competitive Risk: The oncology biotech sector is highly competitive with rapid innovation; competing therapies may limit market opportunities for Anixa's products.

• Anixa Biosciences Inc is a biotechnology company focused on developing therapies and vaccines addressing unmet needs in oncology, particularly ovarian and breast cancers [S1].
• The company’s therapeutics program includes liraltagene autoleucel (lira-cel), a novel CAR-T cell therapy targeting ovarian cancer, developed by its subsidiary Certainty Therapeutics, Inc. [S1].
• Certainty holds an exclusive worldwide license from The Wistar Institute for chimeric endocrine receptor targeted therapy technology, with equity and milestone payment obligations [S1].
• A Phase 1 clinical trial of lira-cel began in August 2022 at the H. Lee Moffitt Cancer Center, with multiple dose cohorts treated and the therapy generally well-tolerated; anecdotal signs of efficacy have been observed [S1].
• Anixa holds exclusive worldwide licenses from Cleveland Clinic for breast cancer vaccine technology targeting alpha-lactalbumin protein, and ovarian cancer vaccine technology targeting AMHR2-ED protein [S1].
• The breast cancer vaccine Phase 1 trial, fully funded by a U.S. Department of Defense grant, enrolled multiple cohorts including early-stage triple-negative breast cancer (TNBC) patients and high-risk individuals, with the vaccine reported as safe and well-tolerated, and immune responses observed [S1].
• Final Phase 1 breast cancer vaccine data presented in December 2025 showed all primary endpoints met, 74% immune response rate, and safety with mainly injection-site irritation; combination with Keytruda showed no major additional side effects [S1].
• The company has a Joint Development and Option Agreement with Cleveland Clinic to develop additional cancer vaccines targeting lung, colon, and prostate cancers using similar mechanisms [S1].
• Anixa’s revenue historically derived from technology licensing and patent sales; no revenue has been generated yet from therapeutics or vaccine programs [S1].
• The company’s liquidity as of July 31, 2026, includes $1.398 million in cash and equivalents, $12.466 million in short-term investments, total current assets of $14.911 million, current liabilities of $1.745 million, with a current ratio of 8.54 and cash ratio of 7.94 [S2].
• Net loss for the quarter ended July 31, 2026, was $2.606 million with basic and diluted EPS of -$0.08 [S2].
• Recent news highlights include patent grants for breast cancer vaccine technology in Australia and South Korea, and a notice of allowance for the same technology in China [N3][N4][N5].
• The company’s breast cancer vaccine was reported safe and well-tolerated in Phase 1 clinical trials [N7].
• D. Boral Capital maintained a buy recommendation on Anixa Biosciences in late 2025 [N6].